Trial
NCT00702923
CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Wisconsin, Madison
Collaborators
Pfizer
Condition
Prostate Cancer
Intervention
Bicalutamide and CP-675,206 (Tremelimumab)
Why stopped
Enrollment was halted prematurely due to slow accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-21